AmerisourceBergen to Support Commercialization of Krystal Biotech’s Gene Therapy
The U.S. Food and Drug Administration (FDA) today approved Krystal Biotech, Inc.’s VYJUVEK™ (beremagene geperpavec-svdt) for the treatment of patients six months of age or older with dystrophic epidermolysis bullosa. As part of its agreement with Krystal Biotech, AmerisourceBergen will serve as the exclusive specialty distributor of the product. AmerisourceBergen’s commercialization support is expected to include third-party logistics, including cGMP kitting, storage and distribution of the frozen products.
“Cell and gene therapy products can transform how certain diseases are treated, offering significant promise for patients around the world. Our goal is to provide developers with access to services across the product lifecycle to simplify the commercialization process and help them achieve the outcomes they desire,” said Lung-I Cheng, Vice President of Cell & Gene Therapy at AmerisourceBergen. “We are thrilled to support Krystal Biotech and look forward to providing the services needed to help them drive commercial success and ensure patients have timely and reliable access to the treatment.”
Accelerating healthier futures
As healthcare advances, so must the processes that connect patients to the therapies they need. Each patient's path to treatment is unique. And because a rapidly evolving cell and gene therapy industry requires an equally innovative partner, AmerisourceBergen is committed to delivering solutions that enable this connection.
Every innovator needs a connector. We exist to connect you.
Related content
Cencora.com is providing automated translations to assist in reading the website in languages other than English. For these translations, reasonable efforts have been made to provide an accurate translation, however, no automated translation is perfect nor is it intended to replace human translators. These translations are provided as a service to users of Cencora.com and are provided "as is." No warranty of any kind, either expressed or implied, is made as to the accuracy, reliability, or correctness of any of these translations made from English into any other language. Some content (such as images, videos, Flash, etc.) may not be accurately translated due to the limitations of the translation software.
Any discrepancies or differences created in translating this content from English into another language are not binding and have no legal effect for compliance, enforcement, or any other purpose. If any errors are identified, please contact us. If any questions arise related to the accuracy of the information contained in these translations, please refer to the English version of the page.